Analisis Adverse Drug Reactions (Adrs) Dan Penanganannya Pada Pasien Kanker Payudara Dengan Regimen Paclitaxel-Epirubicindi Rsud Dr. Moewardi Surakarta

Ayu Wicaksono, Winda and -, Prof. EM Sutrisna (2022) Analisis Adverse Drug Reactions (Adrs) Dan Penanganannya Pada Pasien Kanker Payudara Dengan Regimen Paclitaxel-Epirubicindi Rsud Dr. Moewardi Surakarta. Thesis thesis, Universitas Muhammadiyah Surakarta.

	PDF (Naskah Publikasi) NASKAH PUBLIKASI.pdf Download (771kB)
	PDF (Halaman Depan) Halaman Depan rev...pdf Download (710kB)
	PDF (Bab I) Bab I.pdf Download (208kB)
	PDF (Bab II) Bab II.pdf Restricted to Repository staff only Download (573kB) | Request a copy
	PDF (Bab III) Bab III.pdf Restricted to Repository staff only Download (581kB) | Request a copy
	PDF (Bab IV) Bab IV.pdf Restricted to Repository staff only Download (470kB) | Request a copy
	PDF (Bab V) Bab V.pdf Restricted to Repository staff only Download (190kB) | Request a copy
	PDF (Daftar Pustaka) Daftar Pustaka.pdf Download (454kB)
	PDF (Lampiran) Lampiran.pdf Restricted to Repository staff only Download (1MB) | Request a copy
	PDF (Surat Pernyataan Publikasi) SURAT PERNYATAAN PUBLIKASI KARYA ILMIAH_001.pdf Restricted to Repository staff only Download (90kB) | Request a copy

Abstract

Breast cancer is one of the leading causes of death in the world, especially in women. The incidence of breast cancer in Indonesia is considered high, one example is Central Java which is the province with the highest incidence of breast cancer in 2013. Chemotherapy is one of the treatment options that are often recommended for breast cancer patients and is considered effective but has a negative impact on several patients. patients in the form of Adverse Drug Reactions (ADRs) due to the therapeutic regimen used. This study aims to describe the incidence of ADRs in patients undergoing chemotherapy with the Paclitaxel-Epirubicin regimen, the effectiveness of its treatment, and the risk factors that influence the incidence of ADRs. This research was conducted in RSUD Dr. Moewardi Surakarta with a cross-sectional design prospectively through direct patient interviews, equipped with laboratory data and the patient's clinical condition. Of the 57 patients observed, the most ADRs were experienced by patients with an age range of 41-50 (35.1%) and 51-60 (35.1%) and was dominated by patients with comorbidities by 52.6%. Patients with breast cancer are generally in stage 3 with the most chemotherapy cycles being the third cycle. Patients undergoing chemotherapy underwent hospitalization with different durations and the most patients underwent 1 and 2 days of hospitalization. The most ADRs experienced by patients undergoing chemotherapy with the Paclitaxel-Epirubicin regimen were alopecia in 57 patients (20.2%), nausea in 52 patients (18.4%), anemia in 44 patients (15.6%) and followed by motor peripheral neuropathy in 41 patients (14.5%). The severity of ADRs experienced by patients was dominated by severity 1 (mild) which was 57.4% and no patient experienced an emergency or died. The selection of ADRs treatment therapy that the patient underwent was correct, it's just that there were 4 patients who did not experience a decrease in the severity of the ADRs incident. Cancer stage and comorbidities are risk factors that influence the severity of ADRs. Of the two risk factors, the most influential on the incidence of ADRs is the stage of cancer. Patients with end-stage cancer have a tendency to experience ADRs with a severity level of 3,661 times compared to patients with early-stage cancer.

Item Type:	Thesis (Thesis)
Uncontrolled Keywords:	ADRs, breast cancer, chemotherapy, paclitaxel-epirubicin, age, chemotherapy cycle, cancer stage, comorbidities
Subjects:	R Medicine > RM Therapeutics. Pharmacology
Divisions:	Fakultas Pasca Sarjana > Magister Farmasi
Depositing User:	Unnamed user with username v100180031
Date Deposited:	24 Feb 2022 06:44
Last Modified:	24 Feb 2022 06:44
URI:	http://eprints.ums.ac.id/id/eprint/98638

Actions (login required)

View Item